Aarti Drugs (AARTIDRUGS) | Stock Overview & Key Data
Aarti Drugs Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹1,026.95 on October 5, 2020
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Aarti Drugs
AARTIDRUGS
|
33.96B Small-cap | 2.55% | 2.08% | 10.70% | -4.44% | -9.90% | -19.85% | -20.05% | -48.38% | 225.65% | 2,200.12% | 3,739.88% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | 0.96% | -3.84% | 1.28% | 0.50% | 4.93% | 7.10% | 82.23% | 170.41% | 143.23% | 656.74% | 2,541.29% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | 1.34% | -2.25% | 8.85% | 4.11% | 4.17% | -0.43% | 85.44% | 58.15% | 496.33% | 1,610.60% | 10,946.76% |
|
Sun Pharma Advanced
SPARC
|
46.75B Small-cap | 12.49% | 39.95% | 100.62% | 67.89% | 69.61% | 34.88% | 14.54% | -3.55% | -20.47% | 148.26% | -23.02% |
|
Innova Captab
INNOVACAP
|
41.43B Small-cap | 8.95% | 10.45% | 34.08% | 34.58% | 28.37% | 3.87% | 74.08% | 74.08% | 74.08% | 74.08% | 74.08% |
|
Gujarat Themis
GUJTHEM
|
35.41B Small-cap | -4.89% | 4.00% | 38.98% | -1.40% | -12.59% | 15.75% | 76.92% | 76.92% | 76.92% | 76.92% | 76.92% |
Ownership & Short Interest
Calculate Your Aarti Drugs Investment Returns
Long-Term Investment Performance Analysis
Aarti Drugs stock price in Jul 2016 was ₹129.81, A ₹1,000.00 lump sum investment in Aarti Drugs made 9 years ago would be worth approximately ₹2,891.92 today, representing a strong return of 189.19%. This translates to an annualized return (CAGR) of 11.31%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is AARTIDRUGS's 52-week high and low?
- In the last 52 weeks, Aarti Drugs reached a high of ₹564.05 (on July 21, 2025) and a low of ₹318.95 (on March 30, 2026).
- What is the market cap and P/E ratio for AARTIDRUGS?
- Curious about Aarti Drugs's size and valuation? Its market capitalization stands at 33.96B. When it comes to valuation, the P/E ratio (trailing twelve months) is 16.37, and the forward P/E (looking ahead) is 14.64.
- Does AARTIDRUGS pay dividends? If so, what's the yield?
- Yes, Aarti Drugs is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.53%, and the company has paid an average of ₹1.33 per share annually over the past 3 years.
- Who are Aarti Drugs's main competitors or similar companies to consider before investing?
When looking at Aarti Drugs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.10% 82.23% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic -0.43% 85.44% Sun Pharma Advanced
SPARC46.75B Healthcare Drug Manufacturers - Specialty & Generic 34.88% 14.54% Innova Captab
INNOVACAP41.43B Healthcare Drug Manufacturers - Specialty & Generic 3.87% 74.08% Gujarat Themis
GUJTHEM35.41B Healthcare Drug Manufacturers - Specialty & Generic 15.75% 76.92% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Aarti Drugs Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Aarti Drugs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 12.28%, the Debt to Equity ratio from the most recent quarter is 39.05, and its Gross Profit Margin stands at 35.74%.
- What is the recent revenue and earnings growth for AARTIDRUGS?
- Looking at Aarti Drugs's growth, its revenue over the trailing twelve months (TTM) was INR25B. Compared to the same quarter last year (YoY), quarterly revenue grew by 8.10%, and quarterly earnings saw a YoY growth of 9.40%.
- How much of AARTIDRUGS stock is held by insiders and institutions?
- Wondering who owns Aarti Drugs stock? Company insiders (like executives and directors) hold about 59.48% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 11.04%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.